All issues
Volume 58 (2012)
- Issue 6 Pages 255-
- Issue 5 Pages 197-
- Issue 4 Pages 143-
- Issue 3 Pages 101-
- Issue 2 Pages 51-
- Issue 1 Pages 1-
- Issue Suppl.1 Pages S･･･
Volume 58, Issue Suppl.1
Displaying 1-15 of 15 articles from this issue
- |<
- <
- 1
- >
- >|
The 17th Japan Head and Neck Cancer Chemotherapy Conference Group (JHNCCCG)
-
[in Japanese]2012 Volume 58 Issue Suppl.1 Pages S1-S2
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSDownload PDF (568K) -
Iwao SUGITANI2012 Volume 58 Issue Suppl.1 Pages S3-S9
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSPatients with thyroid cancer usually have a favorable outcome following standard treatments (surgery, thyroid stimulating hormone suppression and radioactive iodine therapy) ; however, a few with radioactive iodine (RAI) -refractory differentiated thyroid cancer (DTC ; papillary and follicular), poorly or undifferentiated thyroid cancer and locally advanced or metastatic medullary thyroid cancer (MTC) show a poorer prognosis. Recently, several molecular-targeted drugs including tyrosine kinase inhibitors (TKIs) have been tested for those patients. Vandetanib demonstrated significant efficacy on progression-free survival for patients with advanced MTC in a phase III trial. It is approved by the United States Food and Drug Administration for use in advanced, symptomatic and progressive MTC in 2011. Now, some Japanese institutions are participating in ongoing global, multicenter phase III trials using sorafenib and lenvatinib for patients with RAI-refractory DTC. Patients receiving TKIs should be carefully monitored for distinctive adverse events, including hand-foot syndrome, hypertension, QT-prolongation, severe fatigue, hypothyroidism and so on. It is also imperative to develop proper biomarkers which can predict the efficacy of each drug in the respective patient.View full abstractDownload PDF (610K) -
Makoto TAHARA2012 Volume 58 Issue Suppl.1 Pages S10-S15
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSCetuximab is a chimeric IgG1 monoclonal antibody that specifically blocks the epidermal growth factor receptor. In a randomized trial of radiotherapy with or without cetuximab for locally advanced SCCHN, the addition of cetuximab significantly improved the locoregional control and overall survival without an increase in adverse events. Furthermore, a randomized trial of 5-FU and cisplatin with or without cetuximab for recurrent/metastatic SCCHN demonstrated a significant survival benefit for cetuximab combination arms compared with 5-FU and cisplatin arms alone. SPECTRUM evaluated the safety and efficacy of panitumumab (pmab), a fully human monoclonal antibody against the epidermal growth factor receptor, with platinum-based chemotherapy (CT) vs CT alone in patients with R/M SCCHN. This predefined analysis presents outcomes by tumor HPV status. Pts with HPV (-)R/M SCCHN administered pmab + CT had improved overall survival (OS) and progression-free survival (PFS), whereas no improvement in OS or PFS was observed in pts with HPV(+)tumors. Recently, a lot of global randomized trials of molecular-targeted drugs for SCCHN are ongoing. Therefore, we have to facilitate the timely approval of new drugs by active participation in global clinical trials to eliminate the drug lag.View full abstractDownload PDF (610K) -
Akira KUBOTA2012 Volume 58 Issue Suppl.1 Pages S16-S26
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSThe epidermal growth factor receptor (EGFR) is over-expressed in many patients of head and neck squamous cell carcinoma (HNSCC). The high EGFR expression is associated with poor prognosis. Cetuximab is an IgG1 monoclonal antibody which binds to the EGFR. It is the only targeted agent, which got approval for the treatment of HNSCC, for cetuximab had improved overall survival (OS) time of locoregionally advanced HNSCC patients or incurable (recurrent/metastatic) patients combined with radiotherapy or chemotherapy. However cetuximab plus radiotherapy (BRT) still had some issues which should be resolved by additional clinical studies in the future, such as the efficacy of BRT seemed to be restricted to oropharnygeal carcinoma or treatment in the United States with subgroup analysis. There had been no phase III trial of targeted agency for HNSCC patients which cleared the primary endpoint except for cetuximab. while we have not found any targeted agency which surpassed the outcome of conventional standard treatment for HNSCC patients, ipilimumab of cytotoxic T cell antigen 4 inhibitor and vemurafenib of BRAF mutation inhibitor for malignant melanoma had improved OS time and accepted for the standard treatment. It is expected that many targeted agencies will improve OS time and QOL of HNSCC patients compared to conventional standard treatments in the future.View full abstractDownload PDF (628K) -
[in Japanese], [in Japanese], [in Japanese], [in Japanese]2012 Volume 58 Issue Suppl.1 Pages S27-S35
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSDownload PDF (615K)
-
[in Japanese]2012 Volume 58 Issue Suppl.1 Pages S36-S37
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSDownload PDF (524K) -
Hiroshi NISHINO2012 Volume 58 Issue Suppl.1 Pages S38-S43
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESS[Background] Current goals for the treatment of maxillary sinus carcinoma include preservation of vision, eating, communication, and appearance as well as cure. [Methods] 121 Japanese patients who presented with maxillary sinus carcinoma between 1979 and 2005 were analyzed retrospectively. There were 77 males and 44 females, with a median age of 63 years. All patients underwent multimodality therapy including surgery through a sublabial incision, radiotherapy, and intra-arterial chemotherapy. The regional lymph nodes were treated only in patients with neck involvement. [Results] Mean follow-up period was 79 months. The 5-year overall survival rates and local control rates were 73% and 72%, respectively. The 5-year local control rates for patients with T2 lesions were 71% ; for patients with T3 lesions, 88% ; and for patients with T4a lesions, 60% ; and for patients with T4b lesions, 56%. In patients with squamous cell carcinoma, the 5-year local control rates were 76%. In patients with non-squamous cell carcinoma, the 5-year local control rates were 54%. There was significant difference in local control rates among these groups. [Conclusions] Control of the primary site is important in the curative treatment of maxillary sinus carcinoma. Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy is an effective method for maxillary sinus carcinoma.View full abstractDownload PDF (988K) -
Masakazu MIYAZAKI, Ryuichi HAYASHI, Takeshi SHINOZAKI, Toshifumi TOMIO ...2012 Volume 58 Issue Suppl.1 Pages S44-S51
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSSince 1960's, many institutes treated carcinoma of maxillary sinus with combined therapy : surgery, radiation, and intra-arterial infusion chemotherapy in Japan. On the other hands, surgery followed by radiation or chemoradiation is the standard option of treatment for sinonasal carcinoma in western countries. This study reports the NCCHE's 14-year experience with maxillary squamous cell cancer, treated with surgical resection followed by radiation, or trimodal combination therapy. Eighty-seven previously untreated, T3-T4 status patients with squamous cell carcinoma of maxillary sinus underwent treatment at our division. During the average follow-up period of 85.9 months, the 5-year overall survival and local control rate were 47.3% and 60%, respectively. The 5-year overall survival among the patients had T3 and T4a tumor were 59.0% and 51.6%. However, all patients with T4b tumor died, their median survival time was 9.1 months. Almost all patients had T3 and T4b were treated with trimodal therapy, a third patient of T4a status underwent treatment with surgery followed by radiation. There was no difference in overall survival according to treatment in T4a patients. We should consider the other approach for treatment, like superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of maxillary sinus in future.View full abstractDownload PDF (1070K) -
Akihiro HOMMA, Nobuhiko ORIDATE, Seigo SUZUKI, Fumiyuki SUZUKI, Hiromi ...2012 Volume 58 Issue Suppl.1 Pages S52-S56
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSThis retrospective study aimed to assess the role of salvage surgery for local recurrence after concomitant radiotherapy and superselective arterial infusion of cisplatin (RADPLAT) in patients with squamous cell carcinoma cancer of the maxillary sinus as an initial treatment. Forty-one patients were treated by RADPLAT between 1999 and 2009. Local recurrence in the primary site was observed in 12 patients of whom 9 could undergo further salvage surgery. Primary disease control was achieved in 7 of these patients (successful salvage rate, 58.3%). Successful salvage rates for T3, T4a and T4b primary disease were 66.7% (2/3), 66.7% (4/6) and 33.3% (1/3), respectively. The 5-year overall survival rate was 73.6% in all patients. Severe postoperative complication was seen in one patient. Prognosis of patients with locally recurring maxillary sinus squamous cell carcinoma after RADPLAT is relatively good. This is because residual/recurrent tumor was located in anterior portion of the face in most cases. This result should be taken into consideration when the initial treatment plan is decided and the choice of salvage surgery for such recurrent cases should be carefully determined.View full abstractDownload PDF (737K) -
Yasushi FUJIMOTO, Masazumi FUJII, Yuzuru KAMEI, Shunjiro YAGI, Kiyoshi ...2012 Volume 58 Issue Suppl.1 Pages S57-S63
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESS[OBJECTIVE] There are limited data regarding outcome analysis in patients who have undergone craniofacial resection of T4 squamours cell carcinoma of maxillary sinus. The purpose of this study was to evaluate the survival rate of patients with maxillary cancers invading the infratemporal fossa who underwent anterolateral skull base resection. [METHODS] At Nagoya University Hospital, 126 patients underwent craniofacial resection during 21-year period. Among them, 34 patients underwent anterolateral cranial base resections for T4 maxillary squamous cell carcinoma ; 21 cases were stage T4a and 13 tumors were in stage T4b according the UICC (7th edition) classification, and 4 cases were with Cavernous sinus resection. The median follow-up time was 38.7 months (range 12 to 158). [RESULTS] The 5-year survival rate was 60.3% (T4a : 75.1%, T4b : 51.3%), and the relapse-free survival rates was 43.7% (T4a : 46.8%, T4b : 39.9%) at 5 years, respectively. Univariate analysis showed that surgical margin and recurrent disease had a significant effect on the five-year overall survival and disease-free survival. [Conclusion] Anterolateral skull base resection is an effective treatment for T4 maxillary cancer. Patients with positive surgical margins show a poorer prognosis. The mortality and the morbidity is acceptable without cavernous sinus resection.View full abstractDownload PDF (1354K) -
[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...2012 Volume 58 Issue Suppl.1 Pages S64-S73
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSDownload PDF (620K)
-
[in Japanese]2012 Volume 58 Issue Suppl.1 Pages S74-S75
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSDownload PDF (529K) -
Yukinori TAKENAKA, Hidenori INOHARA2012 Volume 58 Issue Suppl.1 Pages S76-S80
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSIncreasing number of patients with head and neck cancer has been treated with chemoradiation therapy, as organ preservation therapy, rather than surgery. However, acute and late toxicity from chemoradiation often cause poor quality of life. The human papillomavirus (HPV) has been identified as the causative agent of a growing subset of oropharyngeal cancer (OPC). Recent studies have demonstrated that the HPV status determines the prognosis of oropharyngeal cancer. The Survival rate of HPV positive OPC treated with chemoradiation have been reported to be as high as 80-90%. Based on these results, some groups are evaluating whether similar good response could be achieved with de-escalation treatment. The strategies for de-escalation are dose reduction of chemoradiation or bioradiation with anti-EGFR antibodies. On the other hand, it has been demonstrated that patients with HPV positive OPC treated with conventional radiotherapy alone can achieve good treatment response. This result prompted us to conduct the clinical trial in which patients with HPV positive OPC receive 70 Gy of intensity modulated radiotherapy. The tailor made therapy for OPC based on its HPV status is now under investigation. Good prognosis as well as better functional outcome can be achieved by the de-escalation strategy in the near future.View full abstractDownload PDF (881K) -
Hidenori SUZUKI, Yasuhisa HASEGAWA2012 Volume 58 Issue Suppl.1 Pages S81-S83
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSWe investigated the relationship between pretreatment FDG uptake, assessed by FDG-PET/CT and overall survival in hypopharyngeal squamous cell carcinoma. Thirty-one patients who underwent pretreatment FDG-PET/CT were newly diagnosed as hypopharyngeal squamous cell carcinoma and received radical therapy. SUVmax was used as FDG uptake, and overall survival rate was calculated by the Kaplan-Meier method. Patients with SUVmax ≥ 13 were significantly shorter overall survival in univariate analysis (p < 0.05). FDG uptake assessed by FDG-PET/CT in hypopharyngeal squamous cell carcinoma has implications for translational research.View full abstractDownload PDF (645K) -
[in Japanese], [in Japanese], [in Japanese]2012 Volume 58 Issue Suppl.1 Pages S84-S96
Published: 2012
Released on J-STAGE: December 03, 2013
JOURNAL FREE ACCESSDownload PDF (647K)
- |<
- <
- 1
- >
- >|